Therefore, the generalizability of our findings needs to be confirmed in patients with diabetes who are at lower cardiovascular risk and/or are treated with newly developed glucose lowering drugs such as GLP-1 receptor agonists and SGLT2 inhibitors. Here, SLC5A2 is linked to diabetes mellitus.